

ORDERING PHYSICIAN INFORMATION

Ordering Physician (full legal name)				NPI #					
Facility Name		Tempus Account #		Email (required for report delivery)		Fax			
Facility Address (Street, Unit)		City			State		Postal Code	Country	
Additional person to be copied				Form completed by					
Name		Email/Fax		Facility Name		Name		Email/Fax	Facility Name

PATIENT INFORMATION

Last Name			MI		First Name				
DOB (MM/DD/YYYY)		Medical Record #		Biological Sex F M Unknown		Email		Phone	
Address (Street, Unit)			City			State		Postal Code	Country

BILLING INFORMATION

Primary insurance plan name		Policy #		Group#		Policy Holder Name		Policy Holder DOB	
Patient relationship to policy holder: Self Spouse Child Other:						Bill Type: Insurance Hospital/Institution Self pay/International			

CURRENT CANCER DIAGNOSIS

Biliary		Colorectal	Heme	Pancreatic	Disease Status (select all that apply): Metastatic, refractory, relapsed, or recurrent Other		Stage:	
Bladder		Endometrial	Hepatocellular	Prostate	Date of curative intent surgery (if any):  Current treatment(s) include: Chemotherapy Radiation No Evidence of Disease/none Immunotherapy/ICI, drug name:			
Breast		Esophageal	Melanoma	Renal				
Cancer of Unknown Primary		Gastric	NSCLC	Sarcoma				
Cervical		Head and Neck	Ovarian	Thyroid				
Central Nervous System				Other				
Primary ICD-10 Codes (C, D, & Z codes):					Has the patient had any type of transplant? No Yes; Type:			

TESTING OPTIONS

When ordering xT, Tempus will run CDx if requirements are met, and LDT otherwise.

Comprehensive Therapy Selection <sup>1</sup>		Comprehensive MRD & Disease Monitoring		Individual Test Options	
xT (DNA), xR (RNA), and tailored testing add-ons by current cancer diagnosis		xM (NeXT Personal® Dx) Tissue-informed MRD and disease monitoring test <sup>3</sup>		SOLID TUMOR & HEME	
Liquid biopsy add-ons (select only one): Add xF+ concurrently Reflex to xF <sup>2</sup>		xM for MRD (Minimal Residual Disease) Tissue-free MRD test for resectable CRC		Tumor + Normal: xT + xR (DNA + RNA) xT (DNA) Reflex to xF <sup>2</sup>	
Hereditary add-ons: Add CancerNext-Expanded® <sup>3</sup> ↳ +RNAinsight®		Testing is for 12 months unless total number of draws is entered. Please enter total number of draws: _____  Recurring draw schedule: every 4 weeks <sup>4</sup> every 3 months 1 time every 6 weeks <sup>4</sup> every 6 months		Tumor Only: xT + xR (DNA + RNA) Heme: xT + xR (DNA + RNA)	
				LIQUID BIOPSY HEREDITARY	
				xF+ CancerNext-Expanded® <sup>3</sup> CancerNext® <sup>3</sup> xF ↳ Add +RNAinsight® ↳ Add +RNAinsight®	
				Add-on Tests	
				TISSUE-BASED TESTS	
				PD-L1 (22C3) PD-L1 (28-8) FOLR1 <sup>3</sup> MGMT <sup>3</sup> PD-L1 (SP142) HER2 + FISH Reflex <sup>3</sup> CLDN18 <sup>3</sup> 1p/19q <sup>3</sup> PD-L1 (SP263) MMR c-MET <sup>3</sup>	
				ALGORITHMIC TESTS (see our testing resources website for logistics)	
				IPS TO (RNA) DPYD HRD PurIST™ (RNA, Panc) UGT1A1	

SPECIMEN RETRIEVAL

See Tempus' specimen guidelines for collection instructions and further details.

FFPE Tissue / Bone Marrow Aspirate Submitting pathologist will choose FFPE Tissue if specimen details are not provided.			
Pathology Lab (Name, City)		Specimen Collection Facility	Patient status at time of specimen collection: Office/Non-Hospital Hospital Outpatient Hospital Inpatient
Case Number	Block #	Date of Collection / Biopsy to be scheduled for	Not yet discharged <b>OR</b> Discharge date:
Blood / Saliva / Other			
Mobile phlebotomy Send saliva kit to patient		Sample previously submitted Clinic first draw, mobile phlebotomy subsequent draws (MRD Only)	Patient status at time of specimen collection: Office/Non-Hospital Hospital Outpatient Hospital Inpatient
Date of Collection: Specimen Collection Facility:			Not yet discharged <b>OR</b> Discharge date:

PHYSICIAN SIGNATURE & CONSENT

By signing and/or submitting the order, I certify that (1) the patient has received an explanation of the purpose, risks, and benefits of the ordered test(s); (2) the ordered test(s) are medically necessary and will inform the patient's treatment plan; (3) unless otherwise set forth on this form, the patient has recurrent, relapsed, refractory, metastatic, or advanced stage III or IV cancer; and (4) the patient has provided informed consent that meets the requirements of applicable law for Tempus or its reference lab to: (a) collect and use the patient's samples (including genetic material) and health information and perform the ordered test(s); (b) obtain, receive, and release health information (including test results) as necessary for reimbursement or the processing of insurance claims; (c) retain and use samples and health information for an indefinite period of time in accordance with applicable law; and (d) de-identify such samples and information and use and share the resulting de-identified samples and information in accordance with applicable law.

In addition, I certify that if xT and xF/xF+ are ordered within 30 days of one another, the order is medically necessary because guidelines support the use of testing, turnaround time for tissue result may delay a treatment decision, the tissue is at risk to fail (e.g. small tissue, archived tissue) and I may not have a timely result to make a treatment decision; and/or genomic heterogeneity may cause available tissue to not be completely representative, and I want to make sure I have a complete mutation profile.

Included Attachments:	Copy of patient's progress notes and/or medical records	Copy of recent pathology report	Copy of insurance card
Ordering Physician Signature:	Printed Name (full legal name):		Today's Date (MM/DD/YYYY):

Test Name	Description	Acceptable Specimen(s)	Kit Type
xT CDx	FDA-approved 648-gene DNA sequencing test.	FFPE tissue, normal sample must be blood or saliva	Tempus Tissue <span></span> , Blood <span></span> , Saliva <span></span>
xT LDT	648-gene DNA sequencing test.	FFPE tissue, or blood (EDTA), or bone marrow aspirate (EDTA)	Tempus Tissue <span></span> , Heme <span></span>
xR	Whole transcriptome RNA sequencing test.	FFPE tissue, or blood (EDTA), or bone marrow aspirate (EDTA)	Tempus Tissue <span></span> , Heme <span></span>
xF	105-gene liquid biopsy tests for solid tumors.	Blood (Streck)	Tempus Blood <span></span>
xF+	523-gene liquid biopsy tests for solid tumors.	Blood (Streck)	Tempus Blood <span></span>
CancerNext®	40-gene hereditary cancer tests , powered by Ambry Genetics.	Blood (EDTA) or saliva	Hereditary Blood (DNA) <span></span> , Hereditary Saliva (DNA) <span></span>
CancerNext-Expanded®	77-gene hereditary cancer tests , powered by Ambry Genetics.	Blood (EDTA) or saliva	Hereditary Blood (DNA) <span></span> , Hereditary Saliva (DNA) <span></span>
+RNAinsight®	Germline RNA sequencing add-on, powered by Ambry Genetics.	Blood (PAXgene®)	Hereditary Blood (DNA+RNA) <span></span>
xM (NeXT Personal® Dx)	Tissue-informed test for monitoring cancer, test by Personalis.	Initial test requires: FFPE tissue, blood (EDTA), and blood (Streck). Subsequent tests require: blood (Streck).	Tempus Tissue <span></span> , xM (NeXT Personal® Dx) Blood <span></span>
xM	Tissue-free MRD for resectable CRC.	Blood (Streck)	Tempus xM MRD Blood <span></span>

*xT CDx logistical details: For details on test requirements and reflex protocols, visit [tempus.com/testing-resources](https://tempus.com/testing-resources).*

The following fields are for CancerNext® or CancerNext-Expanded® orders ONLY. Disregard if not testing for hereditary cancers.

RELEVANT CLINICAL HISTORY (Previous cancer diagnosis, GI polyps, etc.)

FAMILY HISTORY

None/No known family history	Unknown	Adopted		
Relationship to patient	Maternal	Paternal	Age at diagnosis	Details of relevant history

ANCESTRY

White/Caucasian	Native American	Middle Eastern
Hispanic	East Asian	Ashkenazi Jewish
Black/African American	South Asian	Other:

BONE MARROW TRANSPLANT

Personal history of allogeneic bone marrow or peripheral stem cell transplant:	Yes	No
Note: Using a blood or saliva sample is not appropriate for patients who have undergone an allogeneic bone marrow or peripheral stem cell transplant.		

PRIOR PERSONAL OR FAMILY HISTORY OF GENETIC TESTING

No personal or family history of molecular and/or genetic testing.

Relationship to patient: Self Family member:

Germline testing \*

Test performed: Results:

Microsatellite instability analysis:  
Stable (MSS)  
Unstable/High (MSI-High)  
Unstable/Low (MSI-Low)

Somatic/tumor testing \*

Test performed: Results:

Immunohistochemical staining  
Proteins present: Proteins absent:

TMP-00013\_2025-11  
Find the most recent documents at [tempus.com/resources/document-library/](https://tempus.com/resources/document-library/)

PAGE 2/2

Phone: 800.739.4137 | Fax: 800.893.0276 | [support@tempus.com](mailto:support@tempus.com)  
600 West Chicago Avenue Suite 510, Chicago, IL 60654 | [tempus.com](https://tempus.com)